Thursday, November 27, 2014 6:03:39 AM
The Forfivo XL patent was supposed to be protected until June 2027 as can be seen here...
http://www.q1medicare.com/PartD-BrandNameDrugPatentExpirationsRX.php?startLtr=D&endLtr=F&startYear=2006&endYear=2100
While Horst had said they had very strong intellectual property rights on Forfivo XL, it obviously wasn't strong enough to prevent a generic from coming into the market 9 years before patent expiration. (2018 is the expected approval time for Wockhardt's ANDA)...
Now the big question was whether Intelgenx will receive licensing revenue! Judging by the court documents, it looks like they will not be receiving licensing revenues. It appears that Wockhardt will sublicense under Edgemont, giving Edgemont sublicensing revenues...
While at first glance it would appear that Intelgenx got nothing out of this deal, a closer look shows that the revenues that Intelgenx receives on sales of Forfivo XL should improve dramatically, albeit, not until 2018, and only on sales within North America because Intelgenx never filed a EMA application for Forfivo XL...
Wockhardt is a global operation based in Mumbai India, so the big question now is, will they want to sell their generic globally as well? And how would they go about that? I guess it really wouldn't matter seeing as how Intelgenx didn't protect their global marketing!
Here is a link to the court document. Bear in mind that listening to the conference call will yield more information than is provided in this court document!
http://www.4shared.com/office/tbfjuCD3ce/Intelgenx_vs_Wockhardt_Settlem.html
Recent IGXT News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 07:45:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:00:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/15/2024 04:15:15 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 07/08/2024 09:23:06 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/08/2024 09:18:26 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/08/2024 06:50:04 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM